Investors ask Allergan to nix Salix, negotiate with Valeant
This article was originally published in Scrip
Executive Summary
Pershing Square Capital Management isn't the only investor pleading with Allergan to end its supposed negotiations to buy Salix Pharmaceuticals and begin discussions toward a merger with Valeant Pharmaceuticals.